Remedent, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REMI research report →
Companywww.remedent.com
Remedent, Inc. , through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products. It primarily provides professional veneers and teeth whitening products for professional and over-the-counter use.
- CEO
- Guy De Vreese
- IPO
- 2006
- Employees
- 3
- HQ
- Gent, BE
Price Chart
Valuation
- Market Cap
- $14.00K
- P/E
- -0.05
- P/S
- 0.01
- P/B
- 0.01
- EV/EBITDA
- 0.06
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 61.17%
- Op Margin
- -12.46%
- Net Margin
- -27.83%
- ROE
- -11.26%
- ROIC
- -4.99%
Growth & Income
- Revenue
- $986.22K · 14.17%
- Net Income
- $-274,446 · 81.64%
- EPS
- $-0.01 · 81.68%
- Op Income
- $-122,890
- FCF YoY
- -145.91%
Performance & Tape
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.44
- Avg Volume
- 18.92K
Get TickerSpark's AI analysis on REMI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 2, 15 | Sternberg Stuart | buy | 399,819 |
| Dec 2, 15 | Sternberg Stuart | buy | 399,819 |
| Jul 24, 13 | Sternberg Stuart | other | 0 |
| Jul 24, 13 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 2,848,408 |
| Jul 18, 13 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 225,000 |
| Jul 19, 13 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 165,000 |
| Jul 19, 13 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 500 |
| Jul 16, 13 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 713,025 |
| Nov 30, 12 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 45,000 |
| Dec 3, 12 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 200,000 |
Our REMI Coverage
We haven't published any research on REMI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate REMI Report →